Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent ... a “Moderate Sell” rating. Its mean price target of $927.08 indicates a robust 67.2% ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.